The Worldwide Market for Liquid Biopsy (by Analyte [ctDNA, cfDNA, Other], by Application - Screening/Drug Monitoring/Diagnostic, by Region [US, Europe, Asia, ROW] and by Type of Cancer)

  • ID: 4343270
  • Report
  • Region: Global, Asia, Europe
  • 210 Pages
  • Kalorama Information
1 of 4

FEATURED COMPANIES

  • Adaptive Biotechnologies
  • Cynvenio Biosystems
  • Foundation Medicine, Inc.
  • Guardant Health, Inc.
  • Natera
  • Resolution Biosciences
  • MORE

The term liquid biopsy encompasses various diagnostic methods that use liquid, non-tissue specimens to provide information that can aid in the diagnosis, treatment and monitoring of cancer. Currently, tissue biopsies, along with imaging techniques, are the standard methods used in the diagnosis of solid cancers, but despite their widespread use, they have many limitations that open the door for other diagnostic technologies in oncology clinical settings.

The Worldwide Market for Liquid Biopsy Contains Markets for the Following:

  • Liquid Biopsy Technology Market Size and Forecast (CTC / ctDNA, cfDNA, EV and Other)
  • Liquid Biopsy Application Market Size and Forecast (Screening, Therapy, Drug Monitoring)
  • Liquid Biopsy Analyte Type Market Size and Forecast (Cancer, Infectious Disease, Other)
  • Liquid Biopsy Geographic Market (US, EU, Asia, ROW)
  • Top Ten Companies
  • Market and Technology Overview
  • Trends in the Market
  • Profiles of Liquid Biopsy Competitors

Liquid Biopsy Testing Applications in Oncology include:

  • Early diagnosis of cancer/ Screening
  • Therapy personalization and monitoring - to help the physician select optimal therapies for individual patients and monitor their efficacy, as well as explore other options of treatment when the patient becomes resistant to current therapies
  • Disease monitoring - to monitor residual disease, disease progression and tumor evolution, and detect recurrence earlier
  • Prognosis of disease evolution
  • Alternative method of testing when tissue samples are difficult/impossible to obtain, or when the primary site of metastatic disease is unknown.

Liquid Biopsy Technologies

The currently available liquid biopsy technologies employ the analysis of various types of analytes, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, proteins, miRNA and mRNA. Among them, ctDNA and CTCs have been the most explored technologies for commercial applications up to the present time.

  • Circulating tumor DNA (ctDNA) encompasses the small fragments of DNA that are believed to originate from the natural and abnormal necrosis and apoptosis processes that tumor cells undergo regularly. ctDNA fragments have the advantage of being available from different types of specimens, including urine, plasma, blood, and cerebrospinal fluid, but are rare and have a short half-life in the bloodstream, which makes their isolation and identification highly challenging. Since many cancer patients shed only very small DNA fragments into the bloodstream, ctDNA-based diagnostic technologies need to be highly sensitive in order to detect such rare events. Furthermore, ctDNA cannot provide information about protein expression, and the analysis of RNA is also difficult and limited using ctDNA. ctDNA may also result from tumor cells killed by therapeutic drugs, and does not capture information about the residual cancer that may not respond to the particular therapy or has become resistant to it.
  • Circulating tumor cells (CTCs) are cancer cells that are believed to detach from primary or secondary tumors and enter the bloodstream, traveling to distant organs, initiating the process of metastasis, and forming new tumors. Similarly to ctDNA, CTC-based tests could offer significant advantages compared to tissue biopsies, as they may be able to capture the heterogeneity of tumors and their genetic evolution during the disease progression and therapy. Compared to ctDNA, CTCs have a longer half-life in blood, and the analysis of viable cells could provide information about protein expression, such as PD-L1 or ER, which is not possible with ctDNA. Also, since CTCs contain intact genomic material from tumors, their analysis can reveal additional information about the biology of cancer and metastasis that is not possible to obtain from ctDNA.
  • Exosomes are nanometer-sized extracellular membrane vesicles secreted by cells in the extracellular environment on a continuous basis. Exosomes circulate in great abundance and are highly stable in all biological fluids, and contain molecular information from their parental cells, included in proteins and various nucleic acids. Moreover, exosomes are involved in many cellular processes and carry information about tumor growth, metastasis, and drug resistance, which is not available from the analysis of circulating free DNA. Despite their advantages, the analysis of exosomes for diagnostic purposes poses various challenges that complicate considerably their use in the development of commercial diagnostics. Due to the complex composition of biological fluids, the detection and isolation of high purity exosomes is a long process that imposes the use of multiple techniques based on various parameters.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Adaptive Biotechnologies
  • Cynvenio Biosystems
  • Foundation Medicine, Inc.
  • Guardant Health, Inc.
  • Natera
  • Resolution Biosciences
  • MORE

1: Executive Summary

  • Introduction
  • Liquid Biopsy Technologies
  • Industry Structure
  • Liquid Biopsy Market Revenues And Forecast
    • Figure 1-1 Global Liquid BiopsyMarketEstimated Breakdown by Geographic Region, 2016
    • Figure 1-2 Global Liquid Biopsy Market Forecastby Geographic Region ($ millions), 2015-2021

2: Liquid Biopsy Technologies

  • Introduction
  • Current Major Liquid Biopsy Technologies

3: Circulating Tumor Dna (Cfdna) Liquid Biopsy

  • Introduction
  • Advantages And Limitations Of Ctdna In Liquid Biopsy
  • Current Ctdna-Based Liquid Biopsy Tests
    • Adaptive Biotechnologies
    • Biodesix
    • Epigenomics
    • Foundation Medicine
    • Genomic Health
    • Guardant Health
    • Myriad Genetics
    • Pathway Genomics
    • Personal Genome Diagnostics
    • QIAGEN
    • Roche Diagnostics
    • Sysmex-Inostics
    • Trovagene
    • Ctdna-Based Liquid Biopsy Tests In Development
    • Adaptive Biotechnologies
    • Biocartis
    • The Worldwide Market for Liquid Biopsy
    • ii July 2017© Kalorama Information
    • Epigenomics
    • Exact Sciences
    • Foundation Medicine
    • Genomic Health
    • GRAIL
    • Inivata
    • Natera
    • Trovagene

4: Circulating Tumor Cells (Ctcs) Liquid Biopsy

  • Introduction
  • Challenges In The Development Of Ctcs-Based Liquid Biopsy Tests
  • CTCS-Based Liquid Biopsy Tests
    • Biocept
    • Cynvenio Biosystems
    • Epic Sciences
  • Gilupi
    • Menarini-Silicon Biosystems
  • Qiagen
  • CTCS-Based Liquid Biopsy Tests In Development
    • Angle
    • Biocept
    • Epic Sciences
    • Janssen Diagnostics

5: Extracellular Vesicles And Other Liquid Biopsy

  • Introduction
  • Liquid Biopsy Tests Based On Extracellular Vesicles
    • Biodesix
    • Exosome Diagnostics
    • Gensignia
    • Hologic
    • MDxHealth
    • OncoCyte
    • QIAGEN
    • Vermillion
    • VolitionRx

6: Liquid Biopsy Industry Analysis

  • Introduction
  • Tiers Of Competition
  • Competitive Factors
  • Significant Market Trends

7: Liquid Biopsy Market Size And Forecast

  • Market Snapshot
    • Figure 7-1 Global Liquid Biopsy Diagnostics Market Estimated Breakdown by Type of Analyte, 2016
    • Figure 7-2 Global Liquid Biopsy Diagnostics Market Estimated Breakdown by Geographic Region, 2016
  • Market Forecast
    • Figure 7-3 Global Liquid BiopsyMarketForecastby Geographic Region ($ millions), 2015-2021

8: Market By Type Of Analyte

  • Circulating Tumor Dna
    • Market Snapshot
    • Revenue Forecast
    • Global Liquid Biopsy Market by Type of Analyte ($ millions), 2015-2021
  • Circulating Tumor Cells
    • Market Snapshot
    • Revenue Forecast
    • Global Liquid Biopsy Market by Type of Analyte ($ millions), 2015-2021
  • Extracellular Vesicles/ Other Analytes
    • Market Snapshot
    • Revenue Forecast
    • Global Liquid Biopsy Market by Type of Analyte ($ millions), 2015-2021

9: Market By Type Of Application

  • Therapy Guidance And Monitoring
    • Market Snapshot
    • Revenue Forecast
    • Figure 9-1 Global Liquid Biopsy Market by Type of Application ($ millions), 2015-2021
  • Diagnosis/ Screening
    • Market Snapshot
    • Revenue Forecast
    • Global Liquid Biopsy Market by Type of Application ($ millions), 2015-2021
  • Disease Prognosis
    • Market Snapshot
    • Revenue Forecast
    • Global Liquid Biopsy Market by Type of Application ($ millions), 2015-2021

10: Market By Type Of Cancer

  • Breast Cancer
    • Market Snapshot
    • Revenue Forecast
    • Figure 10-1 Global Liquid Biopsy Market by Type of Cancer ($ millions), 2015-2021
  • Colorectal Cancer
    • Market Snapshot
    • Revenue Forecast
    • Global Liquid Biopsy Market by Type of Cancer($ millions), 2015-2021
  • Lung Cancer
    • Market Snapshot
    • Revenue Forecast
    • Global Liquid Biopsy Market by Type of Cancer($ millions), 2015-2021
  • Ovarian Cancer
    • Market Snapshot
    • Revenue Forecast
    • Global Liquid Biopsy Market by Type of Cancer($ millions), 2015-2021
  • Prostate Cancer
    • Market Snapshot
    • Revenue Forecast
    • Global Liquid Biopsy Market by Type of Cancer($ millions), 2015-2021
  • Other Cancers
    • Market Snapshot
    • Revenue Forecast
    • Global Liquid Biopsy Market by Type of Cancer($ millions), 2015-2021

11: Liquid Biopsy Company Profiles

  • Top Ten Companies In The Liquid Biopsy Market
  • Biocept, Inc.
  • Epigenomics
  • Foundation Medicine, Inc.
  • Genomic Health
  • Guardant Health, Inc.
  • Menarini-Silicon Biosystems
  • Myriad Genetics, Inc.
  • Neogenomics
  • Qiagen N.V.
  • Roche Diagnostics
  • Other Companies Activating In The Liquid Biopsy Market
  • Adaptive Biotechnologies
  • Angle, Plc
  • Biocartis
  • Biodesix
  • Cynvenio Biosystems
  • Epic Sciences
  • Exact Sciences
  • Exosome Diagnostics, Inc.
  • Gensignia
  • Gilupi Gmbh
  • Grail
  • Hologic, Inc.
  • Inivata
  • Mdxhealth
  • Natera
  • Oncocyte
  • Pathway Genomics
  • Personal Genome Diagnostics
  • Resolution Biosciences
  • Rosetta Genomics
  • Sysmex-Inostics, Inc.
  • Trovagene, Inc.
  • Vermillion, Inc.
  • Volitionrx
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Adaptive Biotechnologies
  • Angle, Plc
  • Biocartis
  • Biocept, Inc.
  • Biodesix
  • Cynvenio Biosystems
  • Epic Sciences
  • Epigenomics
  • Exact Sciences
  • Exosome Diagnostics, Inc.
  • Foundation Medicine, Inc.
  • Genomic Health
  • Gensignia
  • Gilupi Gmbh
  • Grail
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Inivata
  • Mdxhealth
  • Menarini-Silicon Biosystems
  • Myriad Genetics, Inc.
  • Natera
  • Neogenomics
  • Oncocyte
  • Pathway Genomics
  • Personal Genome Diagnostics
  • Qiagen N.V.
  • Resolution Biosciences
  • Roche Diagnostics
  • Rosetta Genomics
  • Sysmex-Inostics, Inc.
  • Trovagene, Inc.
  • Vermillion, Inc.
  • Volitionrx
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll